Investor update

06 January, 2024

BSE:532872
NSE: SPARC
BLOOMBERG: SPADV@IN
REUTERS: SPRC.BO
CIN:L73100GJ2006PLC047837

Forward-looking statements

This presentation and its contents should not be distributed, published or reproduced, in whole or part, or disclosed by recipients directly or indirectly to any other person. Any failure to comply with these restrictions may constitute a violation of applicable laws. Accordingly, any persons in possession of this presentation should inform themselves about and observe any such restrictions. This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Peak sales forecast/potential in the presentation represent potential sales of the product/s for the commercialization partner. Forward looking statements are based on certain assumptions and expectations of future events. This presentation should not be relied upon as a recommendation or forecast by Sun Pharma Advanced Research Company Limited ("Company"). Please note that the past performance of the Company is not, and should not be considered as, indicative of future results. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward looking statements.

The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoters or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertakes no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefor. This presentation document may contain certain UPSI (Unpublished Price Sensitive Information). You are advised to handle this information in a confidential manner and share it strictly on a need to know basis only. Anyone in possession of such UPSI should not trade/deal in the securities of the Company, either directly or indirectly. Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015, the Company maintains a Structural Digital Database wherein details of sharing this presentation with you are entered. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations. All brand names and trademarks are the property of respective owners.

Vodobatinib for Parkinson's disease

Study status updates



- Vodobatinib PoC study – PROSEEK is fully enrolled – 513 patients;
- Interim analysis is planned for ~ 85% of patients enrolled in Part 1 of the study (441 patients);
- Broader organization will continue to be blinded to the outcome of the study to protect the integrity of remaining patients; and
- Upcoming milestones:
  - Administrative Interim Analysis data availability – Apr 2024;
  - PROSEEK topline data – Aug 2024;

Vodobatinib for Parkinson's disease

Near term priorities

- **Immediate priorities post PROSEEK read-out include the following:**
  - End of Phase 2 consultation with the USFDA and other regulatory agencies;
  - Completion of the Long Term Extension study;
  - Initiation of Phase 3 studies globally;
  - Finalization and execution of partnering strategy; and
  - Resource mobilization including additional fund raises to fully explore the asset.
- **Registrational plan to be agreed with regulators;**
  - Completing the studies required by regulators for NDA submission;
  - Any additional preclinical work that regulators may suggest; and
  - Manufacturing readiness and risk mitigation.

Vodobatinib for Parkinson's disease

Program risks

- **Vodbatinib addresses a significant unmet need, but translation risks remain:**
  - Translatability of animal models of Parkinson's Disease;
  - Lack of validated target engagement markers;
  - Reproducibility of clinical Proof of Concept studies; and
  - PROSEEK clinical design addresses the translational challenges to the extent possible.
- **Expanding evaluation of Vodobatinib beyond early PD patients needs further validation;**
  - PROSEEK patient population includes early PD patients that have not been treated with L-Dopa;
  - SPARC would explore initial registration in early, treatment naïve setting; and
  - Targeting additional patient sub-types in Parkinson's Disease and other relevant disease areas would require additional time and investment.

Vodobatinib for Parkinson's disease

Market risks

- **Biotechs' approaching key data events attract significant speculative activity:**
  - Exploitative or uninformed attempts to manufacture positive or negative outlook;
  - Significant risks in speculative trading involving uncertain data events; and
  - Investors who intend to 'price-in' Vodobatinib's impact needs to do so after deliberate analysis of sales potential, costs, time to market and potential risks.
- **SPARC is committed to exploring targeted therapies for complex Neurodegenerative diseases:**
  - SPARC will disclose the topline as soon as such information can be safely shared after full analysis and without compromising underlying data;
  - SPARC plans to continue exploration of Vodbatinib in PD and other relevant conditions based on data flow; and
  - We remain committed to exploring c-Abl inhibition, oxidative stress response modulation and other appropriately validated pathways to advance standards of care in neurodegenerative diseases.